BlackRock
ATNM icon

BlackRock’s Actinium Pharmaceuticals ATNM Stock Holding History

BlackRock’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$369K Buy
371,210
+4,279
+1% +$5.09K ﹤0.01% 4604
2025
Q4 		$499K Buy
366,931
+3,445
+0.9% +$5.03K ﹤0.01% 4483
2025
Q3 		$582K Sell
363,486
-104,187
-22% -$170K ﹤0.01% 4422
2025
Q2 		$655K Sell
467,673
-1,479,273
-76% -$2.21M ﹤0.01% 4383
2025
Q1 		$3.13M Sell
1,946,946
-25,095
-1% -$31.9K ﹤0.01% 3841
2024
Q4 		$2.48M Buy
1,972,041
+33,483
+2% +$52K ﹤0.01% 3974
2024
Q3 		$3.64M Buy
1,938,558
+63,133
+3% +$249K ﹤0.01% 3822
2024
Q2 		$13.9M Buy
1,875,425
+166,437
+10% +$1.37M ﹤0.01% 3192
2024
Q1 		$13.4M Buy
1,708,988
+17,074
+1% +$110K ﹤0.01% 3197
2023
Q4 		$8.59M Sell
1,691,914
-72,982
-4% -$376K ﹤0.01% 3472
2023
Q3 		$10.4M Buy
1,764,896
+66,226
+4% +$441K ﹤0.01% 3304
2023
Q2 		$12.6M Buy
1,698,670
+1,151,187
+210% +$9.79M ﹤0.01% 3302
2023
Q1 		$5.17M Buy
547,483
+65,081
+13% +$687K ﹤0.01% 3624
2022
Q4 		$5.14M Buy
482,402
+229,548
+91% +$2.33M ﹤0.01% 3710
2022
Q3 		$1.87M Buy
252,854
+21,038
+9% +$131K ﹤0.01% 4226
2022
Q2 		$1.11M Buy
231,816
+866
+0.4% +$4.92K ﹤0.01% 4495
2022
Q1 		$1.18M Buy
230,950
+2,618
+1% +$13.8K ﹤0.01% 4608
2021
Q4 		$1.37M Buy
228,332
+9,089
+4% +$68.2K ﹤0.01% 4554
2021
Q3 		$1.94M Sell
219,243
-3,289
-1% -$22.9K ﹤0.01% 4334
2021
Q2 		$1.76M Buy
222,532
+22,699
+11% +$178K ﹤0.01% 4334
2021
Q1 		$1.52M Buy
199,833
+179
+0.1% +$1.52K ﹤0.01% 4381
2020
Q4 		$1.56M Buy
199,654
+1,334
+0.7% +$14.5K ﹤0.01% 4108
2020
Q3 		$1.92M Sell
198,320
-102,388
-34% -$1.13M ﹤0.01% 3914
2020
Q2 		$3.17M Buy
300,708
+233,790
+349% +$1.77M ﹤0.01% 3691
2020
Q1 		$390K Buy
66,918
+27,601
+70% +$196K ﹤0.01% 4103
2019
Q4 		$257K Buy
39,317
+23,374
+147% +$161K ﹤0.01% 4288
2019
Q3 		$110K Buy
15,943
+55
+0.3% +$383 ﹤0.01% 4428
2019
Q2 		$117K Buy
15,888
+76
+0.5% +$764 ﹤0.01% 4439
2019
Q1 		$228K Buy
15,812
+62
+0.4% +$990 ﹤0.01% 4222
2018
Q4 		$183K Buy
15,750
+76
+0.5% +$1.3K ﹤0.01% 4249
2018
Q3 		$348K Buy
15,674
+21
+0.1% +$427 ﹤0.01% 4203
2018
Q2 		$301K Sell
15,653
-5,966
-28% -$75.6K ﹤0.01% 4224
2018
Q1 		$237K Sell
21,619
-292
-1% -$4.96K ﹤0.01% 4175
2017
Q4 		$437K Buy
21,911
+1,131
+5% +$22.7K ﹤0.01% 4077
2017
Q3 		$358K Buy
20,780
+642
+3% +$14.1K ﹤0.01% 4118
2017
Q2 		$737K Sell
20,138
-3,255
-14% -$136K ﹤0.01% 3926
2017
Q1 		$1.06M Buy
+23,393
New +$898K ﹤0.01% 3802

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock's ATNM Position: Q1 2026 in Review

BlackRock increased its Actinium Pharmaceuticals (ATNM) stake by 1.2% in Q1 2026, buying an estimated $5.09K and bringing the position to 371,210 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #4604.

BlackRock first reported a position in ATNM in Q1 2017 and has held it in 37 quarters since. The position peaked at $13.9M in Q2 2024. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • BlackRock held 371,210 shares of Actinium Pharmaceuticals worth $369K as of Q1 2026.
  • BlackRock bought 4,279 Actinium Pharmaceuticals shares in Q1 2026, an estimated $5.09K.
  • Actinium Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4604 holding.
  • BlackRock first reported a position in Actinium Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
  • BlackRock's Actinium Pharmaceuticals position peaked at $13.9M in Q2 2024.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.